



2024/8/29

產業類別	生技
投資建議	買進 
收盤價	目標價
NT\$ 760.00	NT\$ 1025.00

本次報告：法說會

交易資料

潛在報酬率 (%)	35.26
52 週還原收盤價區間 (NT\$)	547.48-940.36
市值 (NT\$百萬元)	77440
市值 (US\$百萬美元)	2,424
流通在外股數 (百萬股)	102.00
董監持股 (%)	28.66
外資持股 (%)	12.64
投信持股 (%)	2.42
融資使用率 (%)	14.85

財務資料

	2023
股東權益 (NT\$百萬元)	9,085
ROA (%)	12.67
ROE (%)	44.52
淨負債比率 (%)	53.03

公司簡介

海外營收佔比逾九成，公司組織架構涵蓋兩大事業體，即全球 CDMO 業務與全球銷售業務。2Q24 年營收中，CDMO 及全球銷售業務佔比分別為 28% 及 72%，其中在全球銷售業務中，DLS、Branded NDA、Specialty、Other US generics、SW+BH 及 TW 佔比分別為 19%、5%、18%、50%、5%、7% 及 1%。

主要客戶：
主要競爭對手：

陳奕均 fion.chen@sinopac.com

保瑞 (6472 TT)

世界盃之路持續前進


永豐觀點

併購及策略聯盟三箭齊發加計自身成長，保瑞全球業務及 CDMO 業務將持續壯大。

投資評價與建議


維持買進：(1) 在併購 USL、Camden 及與泰福策略聯盟下，保瑞 CDMO 全球業務版圖正式橫跨大小分子藥物，且在能提供客戶一條龍生產服務下，營運動能將加速；(2) 與 USL 併購綜效於 3Q 起陸續顯現下，中長期全球業務之毛利率及獲利還有極大調升空間，維持買進，目標價因 2025 年有一次性處分利益認列，由 992 元調升至 1025 元(20 X 2025 EPS+1X 一次性處分利益約 15 元稅後 EPS)。

近八季營收及 YoY 趨勢圖



資料來源：CMoney；永豐投顧研究處整理，Aug. 2024

近八季營業利益及毛利率趨勢圖



資料來源：CMoney；永豐投顧研究處整理，Aug. 2024

營運現況與分析

公司簡介：保瑞為台灣第一大藥廠(依製造量)，旗下藥品銷售區域涵蓋全球 100 個以上國家，海外營收佔比逾九成，公司組織架構涵蓋兩大事業體，即全球 CDMO 業務與全球銷售業務，2Q24 年營收中，CDMO 及全球銷售業務占比分別為 28% 及 72%，其中在全球銷售業務中，DLS、Branded NDA、Specialty、Other US generics、SW+BH 及 TW 佔比分別為 19%、5%、18%、50%、5%、7%及 1%。

併購及一次性廉價利益認列，2Q 獲利大幅優於預期：保瑞 2Q 營收 50.3 億元(+75.9%QoQ、+60.2%YoY)，兩大業務表現，CDMO 部分，年增 13%，共計上半年新增 6 個新客戶及 14 個新專案，全球銷售業務在 4 月起開始認列 USL 營收，加上亞洲市場西藥銷售及保健品代理業務表現佳下，營收 YoY 成長幅度達 86%，毛利率及費用部分皆受併購 USL 一次性人事等相關調整影響，毛利率由前季 52.7%降至 38.8%，費用由前季 6.1 億元跳增至 12.1 億元，預期 3Q 起費用將回至 9 億左右正常水位，惟業外認列約 8 億元購併 USL 廉價購買利益，整體稅後淨利 11.7 億元(+63.6%QoQ、+69.3%YoY)，稅後 EPS 11.61 元，優於預期之 8.51 元。

積極透過併購擴大全球銷售與 CDMO 接單量能：保瑞繼先前併購安成順利進軍美國市場銷售業務外，因應美國市場在地化生產趨勢，公司今年也陸續啟動三起併購及策略聯盟案

- (1) 美國百年藥廠 USL：保瑞於今年 4 月併入美國 USL 藥廠後，經過一季度的人事等相關調整後，3Q 起公司已把美國市場相關藥品銷售併入 USL 物流系統有效節省倉儲、運輸等費用外，銷售品項整合上，合併後預計將有逾 80 項涵蓋品牌新藥、品牌學名藥、505(b)2 等商業量產藥品，除近期已上市兩項藥品 Torpenz (Everolimus) Tablets(結節性硬化症)及 Brimonidine 0.15%(青光眼及高眼壓)外，還有 10-20 項在研中產品，另因 USL 廠區擁有一年 50 億顆固體口服劑型產能，保瑞也開始積極進行代工業務爭取下，預期 1Q25 此廠將可開始貢獻小分子藥物 CDMO 業務營收；
- (2) Camden 無菌針劑/充填廠併購：因保瑞在生產製程中缺乏無菌針劑及充填產能，故為提供客戶一條龍 CDMO 服務，保瑞於 8 月下旬公告向美國公司 Emergent BioSolutions Inc. 購買旗下子公司 Camden 無菌針劑/充填廠，由於 Camden 本身就擁有 20 幾個既有客戶，故預計 4Q24 起將可為保瑞帶來每季約 6 億元營收貢獻外，目前保瑞多個小分子及大分子 CDMO 客戶也預計將原委外之充填業務轉由此廠進行，故後續營收貢獻將再擴大；
- (3) 攜手泰福，擴大生物藥產業鏈：保瑞為加速公司在大分子生物藥上之發展，近日也公告與泰福(6541 TT)策略聯盟，即將以旗下子公司保瑞生技(負責大分子業務)1 股換 1 股方式，取得泰福 30.5%股權及四席董事且由保瑞董事長盛保熙先生擔任泰福董事長，預計 1Q25 完成交割後，除有約 20 億元處分利益外(以 8/26 股價計算，約可貢獻保瑞稅前 EPS 20 元)，保瑞將以長期投資之業外投資損益項認列，以泰福目前每年虧損約 15-20 億估算，未調整前影響保瑞稅前 EPS 約 4.5-6 元，然因泰福目前兩項藥品 TX01 及 TX05 已開發完成，後續研發費用支出將可大幅降低，加上保瑞甫併購之無菌針劑廠客戶也為泰福美國廠 CDMO 業務潛在客戶下，預期策略聯盟後泰福虧損應可快速收斂。

財務預估：由於 2Q 獲利表現優於預期且 4Q 無菌針劑廠將加入營收貢獻，調整保瑞 2024 年營收預估由 180.9 億元至 184.7 億元(+30.1%YoY)，毛利率 46.6%(原估 47.6%)，稅後淨利 37.1 億元(+22.5%YoY)，稅後 EPS 36.55 元(原估 33.55 元)，2025 年營收 250.3 億元(原估 228.1 億元，+35.5%YoY)，毛利率 45.8%(原估

43.8%)·稅後淨利 66.5 億元(其中有 20 億為入主泰福換股處分利益·+79.3%YoY)·
稅後 EPS 65.53 元(原估 45.07 元)。

附表一：當年度損益表

單位：百萬元	24Q1	24Q2	24Q3F	24Q4F	2024F
營業收入	2,857	5,027	5,050	5,538	18,473
營業毛利	1,506	1,951	2,379	2,775	8,610
營業利益	892	743	1,429	1,844	4,908
稅前淨利	984	1,512	1,061	1,477	5,033
稅後純益	716	1,172	756	1,068	3,712
稅後 EPS (元)	7.03	11.61	7.42	10.48	36.55
營收 QoQ 成長率	-10.86	75.93	0.46	9.66	--
營收 YoY 成長率	-40.23	60.18	64.23	72.79	30.09
毛利率	52.70	38.81	47.11	50.11	46.61
營益率	31.22	14.77	28.30	33.30	26.57
稅後純益率	26.02	24.14	14.97	19.28	20.09

資料來源：CMoney；永豐投顧研究處整理，Aug. 2024

附表二：五個年度損益表

單位：百萬元	2021	2022	2023	2024F	2025F
營業收入	4,900	10,494	14,200	18,473	25,034
%變動率	172.28	114.18	35.31	30.09	35.52
營業毛利	1,672	2,913	6,991	8,610	11,457
毛利率 (%)	34.12	27.76	49.23	46.61	45.77
營業淨利	1,046	1,922	5,249	4,908	7,596
稅前淨利	1,024	1,840	4,064	5,033	9,086
%變動率	71.98	79.69	120.88	23.84	80.53
稅後純益	750	1,392	3,030	3,712	6,654
%變動率	29.62	85.65	117.70	22.51	79.26
稅後 EPS * (元)	10.04	14.26	30.20	36.55	65.53
市調 EPS * (元)	7.74	16.05	31.42	35.86	--
PER (x)	75.70	53.30	25.17	20.80	11.60
PBR (x)	16.49	12.70	8.47	7.52	5.06
每股淨值 * (元)	46.09	59.82	89.68	101	150.08
每股股利 (元)	3.50	8.00	12.00	--	--
殖利率 (%)	2.83	2.57	1.91	--	--

* 以目前股本計算


資料來源：CMoney；永豐投顧研究處整理，Aug. 2024

營運基本資料


同業比較

代號	公司	投資建議	目前股價	市值(億)	稅後 EPS		PE		PB	
					2023	2024	2023	2024	2023	2024


近三年單月營收狀況




近三年單季營收 VS 毛利率趨勢圖




負債比率 VS 存貨周轉天數



歷史 PE 圖



歷史 PB 圖



臺北	永豐證券投資顧問股份有限公司 臺北市忠孝西路一段 80 號 14 樓 電話：(886-2) 2361-0868	永豐金證券股份有限公司 臺北市重慶南路一段 2 號 17 樓 電話：(886-2) 2311-4345
----	---	---

香港	永豐金證券(亞洲)有限公司 香港銅鑼灣新寧道 1 號 7 樓 電話：(852) 2586-8288
----	---

上海	永豐金證券(亞洲)有限公司上海代表處 中國上海市浦東新區世紀大道 1528 號陸家嘴基金大廈 1903A-2 室 電話：(86-21) 6228-8220
----	---

責任聲明

本報告內容僅供參考，客戶應審慎考量本身之需求與投資風險，本公司恕不負任何法律責任，亦不作任何保證。本報告中之內容或有取材於本公司認可之來源，但並不保證其真實性或完整性；報告中所有資訊或預估，變更時本公司將不作預告，若資料內容有未盡完善之處，恕不負責。此外，非經本公司同意，不得將本報告加以複製或轉載。

110 年金管投顧新字第 024 號

SinoPac 投資評等

B：Buy 買進：未來 12 個月該股票表現將優於大盤

N：Neutral 中立：未來 12 個月該股票表現將與大盤一致

S：Sell 賣出：未來 12 個月該股票表現將落後大盤

Analyst Certification:

For each company mentioned in this research report, the respective analyst(s) who cover the company certifies (certify) that all of the views expressed in this research report accurately reflect his (their) personal views about any and all of the subject issuer(s) or securities. The analyst(s) also certifies (certify) that no part of her (their) compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

SinoPac Research Stock Rating System:

Buy: We think the stock will outperform the broader market over the next 12 months.

Neutral: We think the stock will perform in line with the broader market over the next 12 months.

Sell: We think the stock will underperform the market over the next 12 months.

Global Disclaimer:**Important Disclosures for U.S. Persons**

This research report was prepared by SinoPac Securities Corporation (SinoPac), a company authorized to engage in securities activities in Taiwan. SinoPac is not a registered broker-dealer in the United States and, therefore, is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. This research report is provided for distribution to "major U.S. institutional investors" in reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act").

Any U.S. recipient of this research report wishing to effect any transaction to buy or sell securities or related financial instruments based on the information provided in this research report should do so only through Auerbach Grayson & Company, 20 Wall West 55th Street, New York, NY 10019, a registered broker dealer in the United States. Under no circumstances should any recipient of this research report effect any transaction to buy or sell securities or related financial instruments through SinoPac. Auerbach Grayson & Company accepts responsibility for the contents of this research report, subject to the terms set out below, to the extent that it is delivered to a U.S. person other than a major U.S. institutional investor.

The analyst whose name appears in this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA") and may not be an associated person of Auerbach Grayson & Company and, therefore, may not be subject to applicable restrictions under FINRA Rules on communications with a subject company, public appearances and trading securities held by a research analyst account.

Ownership and Material Conflicts of Interest

Auerbach Grayson & Company or its affiliates does not 'beneficially own,' as determined in accordance with Section 13(d) of the Exchange Act, 1% or more of any of the equity securities mentioned in the report. Auerbach Grayson & Company, its affiliates and/or their respective officers, directors or employees may have interests, or long or short positions, and may at any time make purchases or sales as a principal or agent of the securities referred to herein. Auerbach Grayson & Company is not aware of any material conflict of interest as of the date of this publication.

Compensation and Investment Banking Activities

Auerbach Grayson & Company or any affiliate has not managed or co-managed a public offering of securities for the subject company in the past 12 months, nor received compensation for investment banking services from the subject company in the past 12 months, neither does it or any affiliate expect to receive, or intends to seek compensation for investment banking services from the subject company in the next 3 months.

Additional Disclosures

This research report is for distribution only under such circumstances as may be permitted by applicable law. This research report has no regard to the specific investment objectives, financial situation or particular needs of any specific recipient, even if sent only to a single recipient. This research report is not guaranteed to be a complete statement or summary of any securities, markets, reports or developments referred to in this research report. Neither SinoPac nor any of its directors, officers, employees or agents shall have any liability, however arising, for any error, inaccuracy or incompleteness of fact or opinion in this research report or lack of care in this research report's preparation or publication, or any losses or damages which may arise from the use of this research report.

SinoPac may rely on information barriers, such as "Chinese Walls" to control the flow of information within the areas, units, divisions, groups, or affiliates of SinoPac.

Investing in any non-U.S. securities or related financial instruments (including ADRs) discussed in this research report may present certain risks. The securities of non-U.S. issuers may not be registered with, or be subject to the regulations of, the U.S. Securities and Exchange Commission. Information on such non-U.S. securities or related financial instruments may be limited. Foreign companies may not be subject to audit and reporting standards and regulatory requirements comparable to those in effect within the United States.

The value of any investment or income from any securities or related financial instruments discussed in this research report denominated in a currency other than U.S. dollars is subject to exchange rate fluctuations that may have a positive or adverse effect on the value of or income from such securities or related financial instruments.

Past performance is not necessarily a guide to future performance and no representation or warranty, express or implied, is made by SinoPac with respect to future performance. Income from investments may fluctuate. The price or value of the investments to which this research report relates, either directly or indirectly, may fall or rise against the interest of investors. Any recommendation or opinion contained in this research report may become outdated as a consequence of changes in the environment in which the issuer of the securities under analysis operates, in addition to changes in the estimates and forecasts, assumptions and valuation methodology used herein.

No part of the content of this research report may be copied, forwarded or duplicated in any form or by any means without the prior consent of SinoPac and SinoPac accepts no liability whatsoever for the actions of third parties in this respect.